BioXcel Therapeutics, Inc. (BTAI)
NASDAQ · Healthcare
BioXcel Therapeutics, Inc. Income Statement 2022–2025
| Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | |
|---|---|---|---|---|
| Revenues | ||||
| Revenue | 642,000 | 2.3M | 1.4M | 375,000 |
| Gross Profit | 478,000 | 123,000 | 120,000 | 355,000 |
| Profitability | ||||
| Operating Income | -50.5M | -67.2M | -171.8M | -159.6M |
| EBITDA | — | — | — | — |
| Net Income | -69.9M | -59.6M | -179.1M | -165.8M |
| Per Share Data | ||||
| EPS (diluted) | — | — | — | — |
| Shares Outstanding (dil.) | 12M | 3M | 2M | 28M |
BioXcel Therapeutics, Inc. Income Statement — FAQ
BioXcel Therapeutics, Inc. (BTAI) income statement over the last 4 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see BTAI's income statement history?
The chart and table above show BioXcel Therapeutics, Inc.'s income statement by year and by quarter, including the growth rate.